In conclusion, in the attempt to identify patients early who are at risk of developing fibrosis-like changes as COVID-19 sequelae and to define early intervention strategies, we consider that the release of IL-1α, IFN-α and TGF-β after AIM2 triggering and AIM2 expression on circulating monocytes could predict PC patients who are more likely to undergo fibrotic complications after COVID-19 recovery. This evidence concerns the gene IL1A and COVID-19.